Three new #obesity drugs—high-dose semaglutide, semaglutide plus cagrilintide, and oral orforglipron—may soon be approved in the US. JAMA Medical News Director Jennifer Abbasi and Lead Senior Staff Writer Rita Rubin examine how US$ 23.19 Min. order: 1 piece ★★★★★ 4.2 (111 reviews) Sold : Login>>
GHK-Cu vs NAD+: Which Longevity Peptide Should You Take or Stack? US$ 29.71 Min. order: 1 piece ★★★★★ 4.5 (290 reviews) Sold : Login>>
Incretins in Cardiometabolic Medicine: Leveraging GLP-1, GIP, and Glucagon Receptor Agonism for Cardiovascular Risk Reduction – US$ 23.91 Min. order: 1 piece ★★★★★ 4.0 (283 reviews) Sold : Login>>
Retatrutide Dosage: A Complete Guide US$ 27.81 Min. order: 1 piece ★★★★★ 4.2 (216 reviews) Sold : Login>>
GLP-1 Receptor Agonists for Weight Control: Emerging Insights from Clinical Trials and Future Perspectives US$ 28.56 Min. order: 1 piece ★★★★★ 4.7 (56 reviews) Sold : Login>>